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Actigraphy provides longitudinal sleep data over multiple nights. It is a less expensive
and less cumbersome method for measuring sleep than polysomnography. Studies
assessing accuracy of actigraphy compared to ambulatory polysomnography in different
sleep-disordered patients are rare. We aimed to compare the concordance between
these methods in clinical setting. We included 290 clinical measurements of 281
sleep laboratory patients (mean age 37.9 years, 182 female). Concomitant ambulatory
polysomnography and actigraphy were analyzed to determine the agreement in patients
with obstructive sleep apnea, narcolepsy, periodic leg movement disorder, hypersomnia,
other rarer sleep disorders, or no organic sleep disorder. Bland-Altman plots showed
excellent accuracy, but poor precision in single night results between the two methods
in the measurement of sleep time, sleep efficiency, and sleep latency. On average,
actigraphy tended to overestimate sleep time by a negligible amount, −0.13min, 95%
confidence interval [−5.9, 5.6] min in the whole sample. Overestimation was largest,
−12.8 [−25.1, −0.9] min, in patients with obstructive sleep apnea. By contrast, in
patients with narcolepsy, actigraphy tended to underestimate sleep time by 24.3 [12.4,
36.1] min. As for sleep efficiency, actigraphy underestimated it by 0.18 [−0.99, 1.35] %
and sleep latency by 11.0 [8.5, 13.6] min compared to polysomnography. We conclude
that, in measuring sleep time, actigraphy is reasonably reliable and helpful to be used for
a week or two to exclude insufficient sleep in patients with the suspicion of narcolepsy.
However, the effectiveness of actigraphy in determining sleep seems to decrease in
subjects with low sleep efficiencies.
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INTRODUCTION
Polysomnography (PSG) in a sleep laboratory has remained the gold standard in measuring the
quality of sleep for decades. Technological advancements have refined the method throughout
the years, but also produced alternative methods for sleep measurement that could have many
advantages over PSG in terms of price and ease of usability in the habitual sleep environment (1).
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One of the advantages of actigraphy (ACG) is that it
provides longitudinal sleep data over multiple nights. ACG is
less expensive, less cumbersome, and easier to use than PSG.
ACG is clearly more accurate in estimating sleep time than
sleep logs (2). It is probably the most widespread tool for
assessing circadian rhythm sleep-wake disorders (2). In addition,
its use in measuring different properties of sleep has increased.
In a recent clinical practice guideline, American Academy of
Sleep Medicine (AASM) introduced several recommendations
about the use of ACG in the assessment of patients suspected
with central disorders of hypersomnolence, insufficient sleep
syndrome, sleep-disordered breathing, or insomnia disorders (3).
These recommendations include the use of ACG integrated with
home sleep apnea test devices to estimate total sleep time during
recording in patients suspected of sleep apnea, and to monitor
total sleep time prior to multiple sleep latency test (MSLT) in
patients suspected of narcolepsy (3).
However, compared to PSG, ACG has been reported to
be less reliable in recognizing short periods of wake and to
overestimatemeasured sleep times (4). Based on previous studies,
the validity of ACG somewhat decreases with the decline of
sleep efficiency (2, 5, 6). An essential problem with the field
is that ACG algorithms of different manufacturers lack shared
technical solutions and terms, precluding direct comparisons
(7). Quantitative criteria for the assessment of other aspects of
sleep than circadian rhythm by ACG were missing for a long
time (8–10).
The recent review by AASM set the clinical significance
thresholds for the maximum allowable mean difference and
the maximum allowable 95% confidence interval (CI) in sleep
time between ACG vs. PSG to 40min among patients with
central disorders of hypersomnolence (2). Of note, the task force
identified only one study about the concordance of ACG and PSG
prior to MSLT among subjects with the suspicion of narcolepsy
or hypersomnia (11), and the threshold was set to the same as in
those diseases with more available ACG data, like insomnia and
insufficient sleep syndrome. In addition, the threshold in sleep
efficiency was set to 5% and in sleep latency to 30min, but these
limits were given only for insomnia patients (2).
Only a limited number of actigraphic studies with small
number of subjects has been conducted with patients with
central disorders of hypersomnolence. Over a decade ago,
a study examined the concordance of ACG and PSG prior
to MSLT among subjects with suspicion of narcolepsy or
hypersomnia (11). Recently, effects of different sensitivity
settings of actigraphy regarding its congruence with PSG among
idiopathic hypersomnia patients were studied (12). In young
operated patients with craniopharyngioma, in higher risk for
Abbreviations: AASM, American Academy of Sleep Medicine; ACG, actigraphy;
AHI, apnea-hypopnea index; AST, actual sleep time (in actigraphy); CCC, Lin’s
concordance correlation coefficient; CI, confidence interval; DSPS, delayed sleep
phase syndrome; EDS, excessive daytime sleepiness; EEG, electroencephalography;
ICSD-3, International Classification of Sleep Disorders, third edition; LoA, limit
of agreement; MSLT, multiple sleep latency test; NT1, narcolepsy type 1; NT2,
narcolepsy type 2; OSA, obstructive sleep apnea; PLMD, periodic limb movement
disorder; PSG, polysomnography; RLS, restless legs syndrome; SE, sleep efficiency;
SL, sleep latency; ST, sleep time; TST, total sleep time (in polysomnography).
narcolepsy, PSG, and ACG were also compared recently (13).
Actigraphy in sleep apnea patients has been studied by several
groups (8, 14–16).
According to ICSD-3, narcolepsy is divided to narcolepsy
type 1 (NT1) or narcolepsy type 2 (NT2). NT1 is caused by
a selective destruction of hypothalamic hypocretin-producing
neurons, while the etiology of NT2 is unknown and usually not
hypocretin-related. Patients with NT2 do not have cataplexy,
but the other symptoms—excessive daytime sleepiness, disturbed
sleep, and parasomnias—are shared in NT1 and NT2.
We aimed to compare the concordance of ACG and
ambulatory PSG in subjects having excessive daytime sleepiness
(EDS) or other sleep-related symptoms with or without organic
sleep disorders to see if ACG is reliable in all diagnostic groups,
with a special interest in narcolepsy.
METHODS
The Helsinki and Uusimaa Ethics Committee approved this
study (7/2016). As the study was conducted based on documents
completed during normally scheduled patient visits, no written
informed consent was required.
Subjects
Initially, study material consisted of all consecutive concomitant
ambulatory PSG and ACG recordings conducted at our sleep
laboratory in routine clinical practice in the university hospital
during 4.5 years, in total 314 recordings. Some of the PSGs failed
and, consequently, we included 290 technically reliable enough
sleep studies in the study material. Altogether, the data was
gathered from 281 individual subjects with the remaining nine
recordings being repeated measurements. Actigraphy recordings
did not have any technical problems. Subjects were referred
for suspicion of sleep-related breathing or movement disorders,
central disorders of hypersomnolence, or parasomnias. The
subjects were independent in activities of daily living and did not
require the assistance of an aide.
Measurements
An Actiwatch (Cambridge Neurotechnology Ltd,
Cambridgeshire, UK) or a MotionWare (CamNtech Ltd,
Cambridge, UK) system were used as the ACG devices in this
study. Of note, MotionWare system is the successor to Actiwatch
made by the same manufacturer. Thus, all the parameters used
in this study are identical, and comparable analysis settings were
used. During the preceding afternoon, the subjects were carefully
guided and prepared at the sleep laboratory for the ambulatory
PSG and concomitant ACG and then sent home to sleep in their
own beds for the night. The subjects would then return to the
laboratory the next morning to return the equipment. In several
cases, especially when a central disorder of hypersomnolence
was suspected, the subjects were given the ACG device already
a fortnight beforehand to be worn at all times so that their
circadian rhythms and sleep time could also be evaluated over
multiple nights. If there was no such suspicion, ACG was only
studied one night, concomitantly with PSG.
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The raw data from the ACG devices was processed using
an analysis program provided by the manufacturer. The epoch
length was 1min. The definitions of the used ACG parameters
were described in detail previously (17). As in PSG, sleep latency
(SL) is the difference between bedtime and sleep start, and sleep
efficiency (SE) is the percentage of time spent asleep between
bedtime and get up time. Actual sleep time (AST) in ACG and
total sleep time (TST) in PSG are analogous, both defined as the
amount of sleep between sleep start and sleep end.
An Embla Titanium (Embla, Denver, CO, USA) ambulatory
PSG system was used for the PSG measurements. Ambulatory
PSG comprised six electroencephalography (EEG) derivations,
two electro-oculography channels, submental muscle tonus,
airflow by nasal pressure transducer, thoracoabdominal
respiratory movements, pulse oximeter, body position,
electrocardiogram, and electromyography from tibialis anterior
muscles. PSG recordings were set to start about an hour before
the subject intended to go to bed and to end well after their
estimated get up time in the morning. At home, the subject
wrote down the exact time for lights off and lights on and
also marked them by pressing a button on the ACG device.
Afterwards, the identical analyzed time for both PSG and ACG
was the time from lights off to lights on. When central disorders
of hypersomnolence were suspected and the subject had the
MSLT the following day, they had to get up at least 1.5 h before
the start of the test, while most of the subjects were able to sleep
as long as they wanted. The PSG data was scored manually by
medical specialists with experience in sleep scoring according to
international criteria (18, 19).
Diagnostic Groups
Once the clinical examinations of a subject were complete
and a diagnosis was set, the subject was categorized based on
the diagnosed organic sleep disorder (if any). Narcolepsy was
diagnosed according to ICSD-3 criteria (20). Those patients,
who were diagnosed before 2014, were reclassified to NT1
or NT2 according to ICSD-3. Hypersomnia group comprised
of idiopathic hypersomnia and other hypersomnia syndromes
(ICD-10 code G47.1), and this diagnosis was set strictly according
to ICSD-3 criteria (20). Obstructive sleep apnea (OSA) was
diagnosed if the apnea-hypopnea index (AHI) had a value higher
than 5 per hour. In addition, six patients with narcolepsy also
had mild OSA, three had moderate OSA, and one had severe
OSA as a co-morbidity, but as it did not affect the results, they
were classified to the narcolepsy group. The slight difference in
defining AHI according to older and newer hypopnea criteria did
not affect the results (18, 19).
Periodic limb movement disorder (PLMD) was diagnosed if
the periodic limb movement index during sleep was higher than
15 per hour. Of note, the diagnosis of PLMD cannot be set in
the context of any other sleep disorder (20) and our subjects
were categorized to this group only if they did not have OSA,
narcolepsy, or hypersomnia. To be precise, some subjects in
this group had restless legs syndrome (RLS) symptoms while
awake together with periodic leg movements while sleeping and
their clinical diagnosis was RLS, whereas subjects without RLS
symptoms had PLMD (20). We combined these subgroups in the
study and focused on PSG findings.
The “Others” group included six patients with NREM
parasomnias, three with REM sleep behavior disorder, and two
with irregular sleep-wake rhythm disorder. Subjects in the “No
sleep disorder” group experienced various degrees of tiredness
and/or sleepiness, but no sleep apnea, PLMD, narcolepsy, or
hypersomnia were found in the sleep studies. Almost all of
them slept objectively too little, and probably also the rest had
need for longer sleep than they got. Some had mild depressive
symptoms or stress, but no clinical diagnosis of depression or
anxiety disorder.
Statistical Analyses
The statistical analysis of the data was carried out with IBM
SPSS R© Statistics 24.0 (IBM, Armonk, NY, USA), and Stata/SE
16.1 for Mac (StataCorp, College Station, TX, USA). The
normality of variables were tested by inspecting the skewness
and kurtosis from histograms and Shapiro-Wilk tests. To evaluate
agreement between the two methods, Bland-Altman plots were
drawn (21, 22). Due to non-parametric distribution of the
majority of mean differences, quintile method and logarithmic
transformation as proposed by Bland and Altman were used to
determine additional limits of agreement (23, 24). To account
for the proportional bias, Bland-Altman plots were adjusted for
trend and regression lines as well as Passing-Bablok diagrams
are shown (25). Mean differences were also plotted against PSG
measures since the PSG is considered a golden standard in these
measures. Lin’s concordance correlation coefficients (CCC) with
95% CI using z transformation were calculated to investigate
association (26).
RESULTS
The study material comprised actigraphy and PSG recordings
done to 281 subjects. Their ages varied between 16 and 90 years
(mean 37.9 y) and 62.8% were female. In addition to first-time
recordings, PSG was done twice to nine subjects. In six of those
cases, the reason was a necessary repetition of an MSLT. In the
three remaining cases, the repetition was done to clarify a finding
after some minor technical problems. When analyzed separately,
the results in the group of repeated recordings were consistent
with the other results, and as our aim was to analyze concordance
between the methods in different recordings, not subjects, we
decided to include those repeated recordings, as well. Altogether,
290 recordings were included in this study. The distribution of
diagnosed sleep disorders, which are described in detail in the
methods section, is summarized in Table 1.
Mean differences between the ACG and PSG measures
followed non-parametric distributions (Shapiro-Wilk P < 0.05)
in the whole sample and in other subgroups than narcolepsy,
NT1, NT2, and hypersomnia. Histograms demonstrated high
kurtosis around zero with multiple outliers, which is seen
also in Passing-Bablok plot (Figure 1). An extreme outlier e.g.,
demonstrated a subject with history of Parkinson’s disease,
restless legs, disturbed nocturnal sleep with only 80min of total
sleep in PSG and 386min in ACG. Outliers were kept in the
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TABLE 1 | Diagnostic groups and subgroups.
Diagnostic groups
and subgroups
N Female Male Mean age (SD),
years
OSA 102 48 54 48.1 (14.2)
Narcolepsy 42 24 18 25.7 (9.1)
NT1 37 24 13 25.7 (9.5)
NT2 5 0 5 26.1 (5.1)
PLMD 28 24 4 39.4 (11.9)
Others (parasomnia) 11 4 7 31.8 (12.0)
Hypersomnia 6 4 2 35.3 (19.3)
No organic sleep disorder 101 78 23 33.0 (11.2)
All subjects 290 182 108 37.9 (14.8)
Number, gender distribution, and age on average (standard deviation) in all diagnostic
groups and narcolepsy subgroups (in italics). OSA, obstructive sleep apnea; NT1,
narcolepsy type 1; NT2, narcolepsy type 2; PLMD, periodic limb movement disorder.
FIGURE 1 | Passing-Bablok of sleep time. Dashed line, 95% confidence
interval. Solid line, Passing-Bablok regression line. Y, Passing-Bablok fit.
sample, and non-parametric methods were used as suggested
by Bland and Altman (23). Logarithmic transformation did not
change the distribution of mean differences.
Sleep Time
A priori, we set the clinical significance threshold for mean
difference in sleep time to ± 40min based on the AASM
guidelines (2, 3). The mean difference in the whole sample was
only −0.13min (95% CI −5.9 to 5.6) indicating very low bias
and high accuracy (Table 2). The mean differences were also
in the reference area in all the subgroups. Of all the individual
measurements, 70.7% were in this AASM reference area.
The Passing-Bablok regression of sleep time showed some
but rather low proportional bias in sleep time measures in
ACG compared to PSG (slope estimate 0.92; 95% CI 0.88, 0.97)
(Figure 1). In other words, there is a trend for actigraphy to
overestimate sleep time especially when sleep time is short in PSG
with few extreme outliers (Figure 2).






















































Mean differences and their 95% confidence intervals in sleep time between ACG and
PSG, the proportion of the differences being inside the clinical significant thresholds of
AASM, calculatory limits of agreement, and Lin’s concordance correlation coefficients
and their 95% confidence intervals (P < 0.05 in all) across all diagnostic groups and
narcolepsy subgroups (in italics). CI, confidence interval; AASM, American Academy of
Sleep Medicine; LoA, limits of agreement; CCC, Lin’s concordance correlation coefficient;
OSA, obstructive sleep apnea; NT1, narcolepsy type 1; NT2, narcolepsy type 2; PLMD,
periodic leg movement disorder.
FIGURE 2 | Difference in sleep time compared to total sleep time in PSG.
Dashed line, ± 40min according to AASM criteria. Gray area, 95% confidence
interval for regression line. Solid line, mean difference. PSG, polysomnography;
ACG, actigraphy.
While being very accurate, Bland-Altman plot showed rather
wide (−97.49, 97.23) limits of agreement (LoA). Non-parametric
distribution and outliers increase limits of agreement that are
based on the standard deviation of the bias. In the subgroups
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FIGURE 3 | Trend Bland-Altman plot: difference in sleep time compared to
average of sleep time in PSG and ACG. Dashed line, mean difference. Gray
area, 95% confidence interval for regression line. PSG, polysomnography;
ACG, actigraphy.
wheremean differences followed normal distribution (NT1, NT2,
narcolepsy, and hypersomnia) LoA were clearly narrower. After
removing 5% of the extreme mean differences from both ends—
quintile method for non-parametric distributions as suggested by
Bland and Altman (23)—LoA in the whole sample were −64.49
(95% CI−70.8,−58.1) and 52.24 (95% CI 46.0, 58.5).
In trend Bland-Altman plot, the mean difference was
−53.26 + 0.13∗average, and LoA ± 2.46∗(56.49–0.06∗average)
(Figure 3).
As for concordance correlation, CCC showed high
concordance in groups “no organic sleep disorder” and
“others (parasomnia)” and also in smaller hypersomnia and NT2
subgroups but poor to moderate in other analyses (Table 2). In
total sample, CCC was 0.8454 (95% CI 0.810 to 0.875) which can
be considered as moderate.
Sleep Efficiency
Table 3 depicts the difference of average sleep efficiencies
measured by PSG and ACG, i.e., SE in PSG—SE in ACG.
Overall, ACG tended to underestimate SE by a very small
amount, 0.18, 95% CI [−0.99, 1.35] % in the whole sample.
The underestimation was larger, 6.24 [3.42, 9.05] %, in the
NT1 subgroup than in the NT2 subgroup. The underestimation
was also clear in the others group with mainly patients with
parasomnias. By contrast, in patients with OSA, ACG tended to
overestimate SE.
AASM set the clinical the clinical significance thresholds for
the maximum allowable 95% CI in sleep efficiency between ACG
and PSG to 5% (2). In total, only 55.5% of the measurements
were inside these limits. All the CCCs were poor, except in the
NT2 group.
Sleep Latency
As is seen in Table 4, ACG seems to underestimate sleep
latency in general, overall on average 11.0, 95% CI [8.5,
13.6] min. The underestimation was the largest, 16.8 [11.1,
22.4] min, in the OSA group. The underestimation was
also clear among subjects with no organic sleep disorders.
The sole exception to this underestimation by ACG was
the narcolepsy group in which the actigraphic SL estimates
were very close—on average only 0.049min longer—to SL
in PSG.
AASM set the clinical significance thresholds for the
maximum allowable 95% CI in sleep latency between ACG and
PSG to 30min (2). In total, 89.9% of the recordings were inside
these limits. All the CCCs were poor.
Men and women as a group did not differ statistically
significantly in any of the above-mentioned sleep parameters.
Expectedly, older subjects had shorter sleep time, lower sleep
efficiency, and longer sleep latency, both in PSG and in ACG.
The differences in Bland-Altman analyses or CCCwere negligible
(data not shown).
DISCUSSION
For our knowledge, this is the first study comparing ACG and
PSG at home. Most people sleep better in familiar environment
than in the sleep laboratory (27). As ACG is worn during daily
life, including nights at home, this method gives a more exact
view of how actigraphy typically performs in different sleep
disorders, compared to validation studies with in-lab PSG.
Our results with sleep time were concurrent with previous
findings. In previous studies looking at subjects with the
suspicion of narcolepsy or hypersomnia, ACG underestimated
sleep time by 15.1min (13) or 15.6min (11), while our result
was 24.3min for narcolepsy and 0.75min for hypersomnia group.
Further, the slight overestimation of TST by ACG in the OSA
group is in line with the recent meta-analysis where ACG was
found to overestimate the TST of patients with OSA by 14.5min
(2), while our result was 12.8min. In our study, accuracy was
similar in younger or older subjects, but also opposite results have
been shown (28).
The findings in this study suggest that ACG is a reliable
tool for estimating TST for many but not all patients with
sleep disorders. On average, ACG excelled well in estimating
TST with an extremely small bias, only 7.8 s and 95% CI of <
6min. Our mean results fit very well in the clinical significance
thresholds for the maximum allowable 95% CI of the mean
difference between ACG vs. PSG, set in the recent guidelines
by AASM (2). Nevertheless, the large variety of the results is of
specific concern. While mean differences between the methods
are minor, the results are imprecise in the whole sample. The
threshold for maximum allowable 95% CI in the difference in
sleep time is too strict for 30% of the measurement pairs in our
study. Especially, periodic leg movements and even mild sleep
maintenance insomnia seemed to affect the accuracy of sleep time
in our subjects.
As is seen in Figure 4, actigraphy is accurate when sleep
efficiency is high but much less so when sleep efficiency
decreases. When a subject has low sleep efficiency, they usually
lie immobile but awake, and ACG interprets it as sleep, thus
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TABLE 3 | Concordance of sleep efficiency between actigraphy and ambulatory polysomnography.
Diagnostic groups and subgroups N Mean difference [95% CI], % Inside AASM limits, % LoA, % CCC
[95% CI]
OSA 102 −2.22 [−4.68, 0.24] 51.0 −26.80, 22.36 0.332
[0.173, 0.475]
Narcolepsy 42 5.63 [3.11, 8.15] 42.9 −10.23, 21.49 0.346
[0.116, 0.540]
NT1 37 6.24 [3.42, 9.05] 35.1 −10.31, 22.78 0.327
[0.085, 0.532]
NT2 5 1.14 [−0.33, 2.61] 100 −1.17, 3.45 0.931
[0.591,0.990]
PLMD 28 0.51 [−3.71, 4.72] 53.6 −20.79, 21.81 0.429
[0.124, 0.659]
Others (parasomnia) 11 4.16 [1.89, 6.46] 63.6 −2.57, 10.88 0.644
[0.299, 0.840]
Hypersomnia 6 −0.20 [−3.85, 3.45] 83.3 −7.01, 6.61 0.134
[−0.680, 0.800]
†
No organic sleep disorder 101 −0.17 [1.66, 1.32] 63.4 −14.97, 14.62 0.665
[0.547, 0.757]
All subjects 290 0.18 [−0.99, 1.35] 55.5 −19.68, 20.03 0.464
[0.375, 0.544]
Mean differences and their 95% confidence intervals in sleep efficiency between ACG and PSG, the proportion of the differences being inside the clinical significant thresholds of
AASM, calculatory limits of agreement, and Lin’s concordance correlation coefficients and their 95% confidence intervals (P < 0.05 in all others except the one marked with
†
) across
all diagnostic groups and narcolepsy subgroups (in italics). CI, confidence interval; AASM, American Academy of Sleep Medicine; LoA, limits of agreement; CCC, Lin’s concordance
correlation coefficient; OSA, obstructive sleep apnea; NT1, narcolepsy type 1; NT2, narcolepsy type 2; PLMD, periodic leg movement disorder.
TABLE 4 | Concordance of sleep latency between actigraphy and ambulatory polysomnography.
Diagnostic groups and subgroups N Mean difference [95% CI], min Inside AASM limits, % LoA, min CCC
[95% CI]
OSA 102 16.8 [11.1, 22.4] 84.3 −39,28, 72.82 0.237
[0.121, 0.346]
Narcolepsy 41 −0.049 [−4.1, 4.0] 97.6 −25.34, 25.24 0.352
[0.069, 0.583]
NT1 36 –0.2 [–4.8, 4.4] 97.2 −26.74, 26.36 0.361
[0.060, 0.603]
NT2 5 0.98 [–8.5, 10.4] 100 −13.96, 15.92 −0.401
[−0.901, 0.556]
†
PLMD 27 8.4 [−1.1, 17.9] 92.6 −38.73, 55.47 0.120
[−0.171, 0.392]
Others (parasomnia) 11 3.2 [−2.6, 9.0] 100 −13.75, 20.20 0.541
[0.039, 0.825]
Hypersomnia 6 3.4 [−4.0, 10.8] 100 −10.38, 17.21 0.835
[−0.474, 0.956]
No organic sleep disorder 100 11.8 [8.7, 14.9] 90.0 −18.97, 42.53 0.787
[0.709, 0.846]
All subjects 287 11.0 [8.5, 13.6] 89.9 −32.22, 54.30 0.520
[0.446, 0.588]
Mean differences and their 95% confidence intervals in sleep latency between ACG and PSG, the proportion of the differences being inside the clinical significant thresholds of AASM,
calculatory limits of agreement, and Lin’s concordance correlation coefficients and their 95% confidence intervals (P < 0.05 in all others except the one marked with
†
) across all
diagnostic groups and narcolepsy subgroups (in italics). CI, confidence interval; AASM, American Academy of Sleep Medicine; LoA, limits of agreement; CCC, Lin’s concordance
correlation coefficient; OSA, obstructive sleep apnea; NT1, narcolepsy type 1; NT2, narcolepsy type 2; PLMD, periodic leg movement disorder.
overestimating sleep time heavily. Figure 4 shows also the
opposite situation: subjects with normal or good sleep efficiency
where ACG underestimated sleep time. Most of these subjects
had narcolepsy, especially NT1, or parasomnia. It is a logical
finding when the operating principle of actigraphy is taken into
consideration. Patients with narcolepsy and/or parasomnia may
present abnormal motor behavior in REM and NREM sleep and
periodic limb movements (17, 29). ACG would interpret these
movements as patients being awake although they would in fact
still be asleep.
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FIGURE 4 | Difference in sleep time compared to sleep efficiency in PSG.
Solid line, mean difference. Gray area, 95% confidence interval for regression
line. PSG, polysomnography; ACG, actigraphy.
As for sleep efficiency and sleep latency, there were clear
differences between subjects with no sleep disorder and patients
having narcolepsy or OSA. Our findings were concurrent with
those in previous studies. ACG tends to underestimate sleep
latency, probably since subjects usually lie immobile for a while
before falling asleep (4). Surprisingly, the narcolepsy subgroup
was an exception and was found to have ACG SL measurements
that were very concordant with PSG equivalents. This is probably
because patients with narcolepsy tend to fall asleep abnormally
fast instead of lying immobile but awake. In some cases with
narcolepsy, ACG showed even longer sleep latencies than PSG,
which may be due to the combination of sleep onset REM and
REM without atonia (17, 29). Narcolepsy differs from other sleep
disorders in many ways, and the direction of misestimation of
sleep time and sleep latency by ACG seems to be one of the
differences, at least every now and then.
Periodic leg movements as a disorder or together with another
sleep disorder seemed to deteriorate the agreement in all sleep
parameters. Since periodic limb movements during sleep are
often unrecognized by the patient, it is important to bear
in mind this possibility, especially if there are discrepancies
in the findings. More research is needed to clarify the
effects of sleep-related movement disorders to the reliability
of ACG.
To summarize our core findings, ACG shows excellent
accuracy i.e., negligible bias or mean difference in sleep time and
sleep efficiency, and low bias also in sleep latency. However, the
precision of actigraphy in a single night measurement is rather
poor as demonstrated by e.g., wide limits of agreement and only
moderate number of measurement pairs fitting inside the AASM
reference area (24). Still, precision increases with replication and
since actigraphy is always done across 7–14 nights, regression
toward mean and replication increase precision remarkably.
Insufficient sleep—either behaviorally induced or secondary
to some problems with sleep—is a very common cause of EDS
and, consequently, the background reason for many patient
visits to sleep laboratories. Before conducting more complicated
diagnostic tests, such as PSG or MSLT for narcolepsy diagnosis,
ACG seems to be a practical tool to show that the cause of
EDS could be the lack of adequate amount of sleep related to
individual need instead of any specific sleep disorder. ACG is far
from being perfect, but there is no better method to assess sleep
time across several nights. Actigraphic data is more reliable than
data derived from sleep logs (2, 30).
What is more, an actigraphy recording, lasting for 2 weeks
or longer, is superior to most other methods in showing
delayed sleep phase syndrome (DSPS) or other circadian rhythm
sleep-wake disorders. DSPS is common in adolescents and
young adults—the same age group where narcolepsy often
starts. Actigraphy cannot distinguish between behavioral and
genetic DSPS, but it shows the current sleep and wake times.
DSPS with very late bedtimes often leads to difficulties in
staying awake during the morning hours, and even REM
sleep can occur in MSLT sessions if the patient usually sleeps
until noon.
To avoid false positive diagnoses of narcolepsy, the use of
ACG for at least a week should precede every diagnosis of
narcolepsy based on MSLT results (3, 17, 20, 31). This is of the
utmost importance for the diagnosis of NT2, where cataplexy
and hypocretin deficiency are not found, and the differential
diagnosis for insufficient sleep syndrome and DSPS is thus much
more difficult than in NT1. Naturally, for a narcolepsy diagnosis,
essential symptoms need to be present and all other possible
causes excluded (20).
In our clinic, we always use ACG for a fortnight before
MSLT so that the last night of ACG recording is the PSG
night (ambulatory or in-lab) and we compare the concomitant
findings. Consequently, we know if the PSG night was
typical for the patient and if the results from the preceding
13 nights of ACG recording were accurate. This procedure
substantially increases the reliability of ACG in everyday
clinical practice.
Additionally to the help in diagnostics, ACG can be used to
assess treatment responses, as the method is known to be highly
sensitive in a within-subject design [see Sadeh and Acebo (32)].
There are several illustrative examples of the use of ACG to
demonstrate drug-induced changes in PLMD or narcolepsy or
CPAP-induced changes in OSA (33–36).
Limitations
Some limitations of the study need to be acknowledged. Although
we had an extensive subject base, which included patients having
the most common clinical sleep disorders, we lacked patients
with insomnia as their primary diagnosis. Additionally, the
number of NT2 and hypersomnia patients were very small, as
these diagnoses are rare, when strict diagnostic criteria are used.
In comparing concordance of PSG and ACG, we were especially
interested in whole-night measures used in clinical practice and
we did not do an epoch-by-epoch comparison of the raw data,
which would have enabled us to investigate the sensitivity and
specificity of ACG in more detail.
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Conclusions
Actigraphy can be a practical tool for measuring some
aspects of sleep in situations where PSG is not available for
multiple nights or when a full examination is unnecessary
to start with. In addition to its established use in circadian
rhythm studies, actigraphy is reasonably good at estimating
TST. Thus, it is useful in the diagnostic examinations of
narcolepsy to see if the subject slept sufficiently during the
nights preceding an MSLT for the test to be reliable. However,
extreme care should be taken in interpreting the reported
values, if the subject has other sleep problems than central
disorders of hypersomnolence, as then these values might
be misestimated.
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